Daxor Corp (DXR) News & EventsDXRNews & EventsDaxor Corp

Daxor Trading Halted, Volatility Trading Pause

Daxor trading halted, volatility trading pause

Daxor Secures U.S. Patent No. 12,635,917 B2

Daxor announced that the United States Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 12,635,917 B2, titled "Remote Blood Volume Monitor." The newly issued patent covers innovative systems and methods for the ongoing and remote monitoring of a patient's absolute blood volume status after an initial baseline measurement. By integrating subsequent hematocrit monitoring technologies-including non-invasive optical sensors like photo-plethysmography embedded in smartwatches or other wearable devices-with Daxor's advanced blood volume analysis algorithms, the system provides real-time updates on a patient's total blood volume, plasma volume, and red cell volume without the need for repeated tracer injections.

Daxor's Net Assets Increased to $45.88 Million in 2025

Daxor issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. "Lord Kelvin's timeless scientific principle perfectly encapsulates the mission of Daxor Corporation. In medicine, you cannot effectively treat what you cannot accurately measure. Looking back at the entirety of 2025, our commitment to replacing clinical guesswork with precise measurement - changing healthcare outcomes and economics - has culminated in a truly transformative year for Daxor Corporation... We are particularly pleased to report on our financial performance for the year ended December 31, 2025, demonstrating significant progress and continued growth in our operating business. As of December 31, 2025, Daxor's net assets were $45,887,266, reflecting an increase of $10,094,965 from $35,792,301 at December 31, 2024. On a per-share basis, our Net Asset Value increased to $9.07 per share at December 31, 2025, up $1.82 per share from $7.25 per share at December 31, 2024... Importantly, our operating division continued to show remarkable growth throughout the year. The operating division experienced a 45 percent increase in unaudited revenues for the year ended December 31, 2025, as compared to the year ended December 31, 2024... Additionally, the operating division realized a loss of $268,598 for the entire year of operations due to judicious investment in research and development for the 2025 product launch, ramping commercial sales teams, and production facilities for our next-generation analyzers... To further bolster our balance sheet and support this growth, subsequent to year-end, we successfully closed a $9 million registered direct offering in January 2026, priced at $11.75 per share... Our most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August for our next-generation rapid, compact, portable Blood Volume Analyzer...On February 10, 2026, Daxor Corporation formally announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 back to the Securities Exchange Act of 1934. We anticipate completing the necessary regulatory steps to fully effectuate this change no later than the end of the second quarter if not sooner."